Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
08/2005
08/11/2005US20050176964 Nicotinamide derivatives useful as p38 inhibitors
08/11/2005US20050176718 Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
08/11/2005US20050176700 (2-methoxyphenyl)acetic acid-7-{4-[3-(2-methoxybenzyloxy)-propoxy]phenyl}-3-(2-thiophen-2-ylacetyl)-3,9-diazabicyclo[3.3.1]non-6-en-6-yl-methyl ester; metabolically stable, orally bioavailable and sufficiently soluble; industrial scale; non-peptidic nature, low molecular weight
08/11/2005US20050176683 Hexa-/Tetra-hydro-pyrrolo[1,2-a]imidazole-2,5-dione derivatives; solid phase synthesis
08/10/2005EP1561752A1 Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
08/10/2005EP1086093B1 Tetrahydroquinoline derivatives as glycine antagonists
08/10/2005EP0968158B1 Method of preparing substituted indanones, the substituted indanones and metallocenes prepared therefrom
08/10/2005CN1653064A Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
08/10/2005CN1652771A Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
08/10/2005CN1214029C 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroi-soquinol-2-yl)-5-(2-pyridyl) quinazo line mesylat and polymorphs
08/10/2005CN1214013C HIV replication inhibiting pyrimidines
08/09/2005CA2327029C Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
08/09/2005CA2310627C Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists
08/04/2005WO2005035489A3 Improved synthesis of discodermolide and variants thereof
08/04/2005WO2005000804A3 Substituted indoles and a process for preparing substituted indoles
08/04/2005US20050171354 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for prophylaxis of cardiovascular disorders
08/04/2005US20050171118 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
08/04/2005US20050171061 Phenylsulfanylphenyl and phenyloxyphenyl substituted piperazine compounds; glycine transport inhibitors; for the treatment of psychoses and convulsive disorders: epilepsy, spasticity, and myoclonus
08/03/2005EP1559717A2 Oxabispidine compounds useful in the treatment of cardiac arrythmias
08/03/2005EP1558599A2 Heteroarylpiperidine modulators of chemokine receptor activity
08/03/2005CN1649870A 7-aryl-3, 9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
08/03/2005CN1649868A Process for preparing acid salts of gemifloxacin
08/03/2005CN1649867A Novel 1, 2, 3-substituted indolizine derivatives, inhibitors of FGFs, method for making same and pharmaceutical compositions containing same
08/03/2005CN1649842A 2, 6-quinolinyl and 2, 6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
08/02/2005CA2362339C Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
08/02/2005CA2362337C Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
08/02/2005CA2170020C Retroviral protease inhibiting compounds
07/2005
07/28/2005WO2005033073A3 Spirocyclic heterocyclic derivatives and methods of their use
07/28/2005WO2005016875A3 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
07/28/2005US20050165244 precipitating the citalopram base in crystalline form, and transforming the base into a pharmaceutically acceptable citalopram salt; useful for removing intermediates which are structurally closely related to citalopram
07/28/2005US20050165092 Crystalline base of citalopram
07/28/2005US20050165051 Taxanes having a C7 carbonate substituent
07/28/2005US20050165022 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
07/28/2005US20050163698 Novel graphite nanocatalysts
07/27/2005EP1556382A1 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof
07/27/2005EP1556370A1 Method for the synthesis of a benzimidazole compound
07/27/2005EP1309555B1 Process for making amlodipine maleate
07/27/2005EP1287004B1 Synthetic process for the manufacture of an ecteinascidin compound
07/27/2005CN1646531A Thioxanthine derivatives as myeloperoxidase inhibitors
07/27/2005CN1646528A Polycyclic compounds as potent alpha2-adrenoceptor antagonists
07/27/2005CN1646165A Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
07/26/2005US6921760 Psychotherapeutic agents.
07/26/2005US6921759 For therapy, prophylaxis or delaying the onset of AIDS and infection by HIV
07/26/2005CA2253948C Carboline derivatives
07/21/2005WO2005066148A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
07/21/2005WO2005035490A3 PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS
07/21/2005US20050159466 Production method of isoxazolidinedione compound
07/21/2005US20050159450 Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics
07/21/2005US20050159438 Spirocyclic heterocyclic derivatives and methods of their use
07/21/2005US20050159424 pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or C( .dbd. O)NR6,
07/21/2005CA2552851A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
07/20/2005EP1303514B1 Process for preparing azacycloalkanoylaminothiazoles
07/20/2005CN1642954A Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
07/20/2005CN1642942A Method for manufacture of sertindole
07/20/2005CN1642931A Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
07/20/2005CN1640877A Novel spiro compounds
07/20/2005CN1211386C Antitumoral analogue of Et-743
07/20/2005CN1211368C Amorphous torasemide modification
07/20/2005CN1211367C Prostaglandin agonists and their use to treat bone disorders
07/20/2005CN1211365C Novel salt of perindopril and pharmacetuical composition contg. same
07/19/2005US6919087 And an excipient wherein the pH is within the range of 5.5-7.0; stability; dosage forms
07/14/2005WO2005023761A3 Cytokine inhibitors
07/14/2005WO2004098528A3 Pyrazole-amine compounds useful as kinase inhibitors
07/14/2005US20050154199 Bridged macrocyclic module compositions
07/14/2005US20050154057 Crystalline form of y-aminobutyric acid analog
07/14/2005US20050154051 Method for the preparation of escitalopram
07/14/2005US20050153952 Methods for inhibiting sterol absorption
07/14/2005US20050153942 Heterocyclic inhibitors of MEK and methods of use thereof
07/14/2005US20050151467 Electrochromic salts, solutions, and devices
07/13/2005EP1551802A1 Indole-3-sulphur derivatives
07/13/2005EP1427711B1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents
07/13/2005CN1639136A Oxazolidinone and/or isoxazoline as antibacterial agents
07/13/2005CN1639115A Semicarbazide derivatives and their use as antithrombotics
07/13/2005CN1638768A Thiazole and oxazole derivatives that modulate PPAR activity
07/13/2005CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals
07/13/2005CN1210279C Thiazolo (4,5-D) pyrimidine compounds
07/13/2005CN1210274C Piperazine and piperidine derivatives
07/12/2005US6916815 C-6 modified indazolylpyrrolotriazines
07/12/2005CA2146047C 13-substituted milbemycin derivatives, their preparation and use
07/07/2005WO2005061484A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof
07/07/2005WO2005037052A3 Binding assay with labelled bispidine variant
07/07/2005WO2005033071A3 Toluene methylation process
07/07/2005WO2005009954A3 Method for modulating calcium ion-release-activated calcium ion channels
07/07/2005US20050148777 (2R)-6-chloro-7-isobutyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid; cyclooxygenase-2 mediated disorders
07/07/2005US20050148633 Method for modulating calcium ion-release-activated calcium ion channels
07/07/2005US20050148622 Process for preparing acid salts of gemifloxacin
07/07/2005US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof
07/07/2005US20050148546 Solid phase acid hydrolysis on cation exchange resin; high yield, stability and purity with fewer clean up steps; reduced acid use and recycle; low cost, industrial scale production of glucosamine and salts
07/07/2005CA2550643A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof
07/06/2005EP1549143A2 Antibacterial pyrazole carboxylic acid hydrazides
07/06/2005EP1549141A2 Methods and compositions for the treatment of autoimmune disorders using clofarabine
07/06/2005EP1212320B1 Phenylpiperazines as serotonin reuptake inhibitors
07/06/2005CN1636005A Benzothiazinone and benzoxazinone compounds
07/05/2005US6913740 Graphite nanocatalysts
06/2005
06/30/2005WO2005058895A1 Novel crystalline forms of 2, 3 dimethyl-8- (2, 6-dimethylbenzylamino) -n-hydroxyethyl-imidazo [1, 2-a] pyridine-6-carboxamide mesylate salt.
06/30/2005WO2005058815A2 Ip-10 antibodies and their uses
06/30/2005WO2005058814A2 Biocidal siloxane coating material containing n-halogenated amine and amide functional groups
06/30/2005WO2005058321A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 5 (mGLuR5) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS.
06/30/2005WO2004089890A3 Process and intermediates for preparing benzazepines
06/30/2005WO2004087649A3 Benodiazepine spirohydantoin cgrp receptor antagonists
1 ... 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 ... 105